Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer
"We are thrilled to welcome Dr. Xu during this pivotal time in Medicilon's growth," said Dr. Chunlin Chen, Founder and CEO of Medicilon. "Her extensive expertise and global perspective align with our vision of driving innovation and advancing our international presence." "We are thrilled to welcome Dr. Xu during this pivotal time in Medicilon's growth," said Dr.Chunlin Chen, Founder and CEO of Medicilon. "Her extensive expertise and global perspective align…
PR Newswire
20/12/2024
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 20 December 2024– On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under…
Nasdaq GlobeNewswire
20/12/2024
SciBase letter from the CEO
We have successfully broadened our presence in the US market with more clinics in new states using Nevisense. We have added individual clinics that diagnose and treat a large number of patients with skin cancer to our target groups, which overall expands SciBase business opportunity. In areas with no reimbursement, we now offer the option of paying directly, a so-called cash-pay model. We are currently testing and evaluating this model in California, the model is proven for other technologies…
PR Newswire
20/12/2024
SciBase publishes prospectus
Publication of the Prospectus Publication of the Prospectus The Prospectus that SciBase has prepared in connection with the Rights Issue has today,December 20, 2024, been approved by the Swedish Financial Supervisory Authority. The Prospectus, containing the full terms and conditions of the Rights Issue, and application forms can be obtained from SciBase and Carnegie and are available on SciBase website ( https://investors.scibase.se/en/mid-disclaimer/107/83 ) and on Carnegie's website...
PR Newswire
20/12/2024
Shaping the Future of Nutraceuticals: Trends, Innovations, and Market Outlook…
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=11584039 Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=11584039 Browse in-depth TOC on "Nutraceuticals & dietary supplements Industry Outlook for 2024" 20 – Tables 40 – Figures 80 – Pages Nutraceuticals Industry Developments in 2024 and Predictions for 2025 In 2024, the nutraceuticals & dietary supplements industry witnessed significant growth, driven...
PR Newswire
20/12/2024
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with…
Bagsværd, Denmark, 20 December 2024– Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo, all administered once-weekly. The trial included 3,417 randomised people with obesity or...
Nasdaq GlobeNewswire
20/12/2024
Rare Disease Consulting: Explore How to Address the Low Prevalence and High…
We recognize the scarcity of published data on rare patient populations, the high unmet needs, and the challenges of inaccurate diagnoses. Over the years, we have built an extensive network of Key Opinion Leaders (KOLs) working in the rare diseases domain. Their invaluable insights enable us to help our clients effectively navigate this challenging landscape. We recognize the scarcity of published data on rare patient populations, the high unmet needs, and the challenges of inaccurate…
PR Newswire
20/12/2024
Idorsia provides update on the exclusive negotiations for the global rights to…
Ad hoc announcement pursuant to Art. 53 LR Company announces delay to the targeted timeline for signing a binding agreementCompany in discussions with bondholders to restructure the company's outstanding debt and extend the operational cash runwayAllschwil, Switzerland – December 20, 2024Idorsia Ltd (SIX: IDIA) today provided an update on the ongoing exclusive negotiations for the global rights to aprocitentan. On November 27, 2024, the company announced that it had entered exclusive...
Nasdaq GlobeNewswire
20/12/2024
Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a…
Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) inpatients aged 4 years and older Follows recent approval from China's National Medical Products Administration (NMPA) Pratteln, Switzerland, December 20, 2024 – Santhera Pharmaceuticals (SIX: SANN) announcesthat the Department of Health of Hong Kong, China, has approved AGAMREE® (vamorolone) for use in patients aged 4 years and older. The approval by the DoH of Hong...
Nasdaq GlobeNewswire
20/12/2024
Coway Listed in the Dow Jones Sustainability Asia Pacific Index for the 12th…
Coway has been on the DJSI Asia Pacific for 12 consecutive years and on the Dow Jones Sustainability Korea Index for 7 years running. It is the only Korean company featured in the DHP Household Durables industry category on the DJSI Asia Pacific Index. Coway has been on the DJSI Asia Pacific for 12 consecutive years and on theDow Jones Sustainability Korea Indexfor 7 years running. It is the only Korean company featured in the DHP Household Durables industry category on the DJSI Asia...
PR Newswire
20/12/2024
A Success Story: Digital Opinion Leader Analysis for Cystic Fibrosis Treatments…
Cystic fibrosis is a life-limiting autosomal recessive genetic disorder that primarily affects the lungs and digestive system, caused by mutations in the CFTR gene. According to DelveInsight's latest Cystic Fibrosis Market and Epidem Forecast Report, the estimated total diagnosed prevalent cases of cystic fibrosis in the 7MM in 2023 were ~68K cases. The UK had the highest number of diagnosed cystic fibrosis cases, with nearly 11K, followed by France with 7.5K and Germany with 7K. In the EU4 and…
PR Newswire
19/12/2024
Innocan Pharma Announces Private Placement of Units
Each Unit will be comprised of: (i) one (1) common share in the capital of the Company (each a "Common Share"); and (ii) one (1) common share purchase warrant (each a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of [C$0.28] for a period of four (4) years from the date of issuance. Each Unit will be comprised of: (i) one (1) common share in the capital of the Company (each a " Common Share "); and (ii) one (1)…
PR Newswire
19/12/2024
CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 –…
ORION CORPORATIONSTOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS19 DECEMBER 2024 at 22.45 EET CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel Orion corrects the stock exchange release published on 19 December at 19.00 EET. In the original English stock exchange release the first quote by CEO Liisa Hurme differs from the first quote in the Finnish stock exchange release. The quote in the...
Nasdaq GlobeNewswire
19/12/2024
U.S. Food and Drug Administration issues Complete Response Letter for the…
Company announcement – No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome The FDA concluded that Zealand Pharma's application did not meet the full requirements for substantial evidence to establish the efficacy and safety of the to-be-marketed dose of glepaglutide.Zealand Pharma will continue the dialogue with the FDA to align on the path toward obtaining regulatory...
Nasdaq GlobeNewswire
19/12/2024
Astraveus Secures €7.1M Non-dilutive Funding from the French State
For further information, please contact: Astraveus SASJérémie Laurent, Chief Executive
[email protected]
For further information, please contact: Astraveus SAS Jérémie Laurent, Chief Executive
[email protected]
About Astraveus: Astraveus is aParis -based biotech company dedicated to making cell therapies with maximized quality at order-of-magnitude lower cost. With the unique Lakhesys Benchtop Cell Factory™, Astraveus provides bioprocessing innovation...
PR Newswire
19/12/2024
Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko…
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS 19 DECEMBER 2024 at 19.00 EET Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel Olli Huotari, Senior Vice President responsible for Corporate Functions organization of the Orion Group and Secretary to the Board of Directors of Orion Corporation, and a member of the Executive Management Board of the Orion Group informed earlier of his...
Nasdaq GlobeNewswire
19/12/2024
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
Jean-Paul Kress to join Sanofi's Board of DirectorsParis, December 19, 2024. Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025, replacing Gilles Schnepp who has decided to leave the Board at the end of 2024. Jean-Paul Kress will hold his position for the remainder of Gilles Schnepp's term of office and his appointment will be subject to ratification at the next Ordinary Shareholders' Meeting of Sanofi. Jean-Paul Kress, M...
Nasdaq GlobeNewswire
19/12/2024
ONWARD Medical Receives FDA De Novo Classification and US Market Authorization…
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) ARC-EX System is the first and only FDA approved technology shown to improve hand strength and sensation after chronic spinal cord injuryARC-EX System is an FDA Breakthrough Device and 2024 TIME Magazine Best Invention EINDHOVEN, the Netherlands, Dec.19, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company...
Nasdaq GlobeNewswire
19/12/2024
Smoke Evacuation Systems Market to Hit US$ 266.4 Million by 2029 with 7.3% CAGR…
Browse in-depth TOC on "Smoke Evacuation Systems Market" Browse in-depth TOC on "Smoke Evacuation Systems Market" 455 - Tables56 - Figures401 - Pages Based on product,the smoke evacuation pencil and wand are the largest share in smoke evacuation system market because they serve a very important function of capturing surgical smoke right at the origin from an undiscerned source during electrosurgical and laser-based procedures. Such devices get used with surgical...
PR Newswire
19/12/2024
Cancer Vaccines Market to Hit USD 20.47 Billion by 2032 with 8.6% CAGR |…
Browse in-depth TOC on "Cancer Vaccines Market" Browse in-depth TOC on "Cancer Vaccines Market" 261 - Tables 37 - Figures 439 - Pages The 'type' segment is segmented into preventive and therapeutic vaccines (Neoantigen cancer vaccines and other cancer vaccines). The preventive vaccines segment dominated the market in 2023. The dominance is attributable to the widespread adoption of HPV vaccines (e.g., Gardasil, Cervarix) to prevent cervical cancer and Hepatitis B vaccines…
PR Newswire
19/12/2024
Artificial Intelligence in Healthcare Market to Hit US$ 164.16 Billion by 2030…
Browse in-depth TOC on "Artificial Intelligence in Healthcare Market"455 - Tables54 - Figures386 - Pages Browse in-depth TOC on "Artificial Intelligence in Healthcare Market" 455 - Tables 54 - Figures 386 - Pages The global Artificial Intelligence (AI) in healthcare market is segmented into integrated solutions, niche/point solutions, AI technology, and services, by offering. The integrated solutions segment is accounted for the largest share in 2023. The large share of…
PR Newswire
19/12/2024
GenBio AI Releases Phase 1 of World's First Digital Organism to Transform…
Unlike earlier models that focus on specific aspects of a multi-cellular organism, GenBio AI takes a holistic approach where multiscale foundation models are built in modules and integrated into a single system. These State-Of-The-Art models are unprecedented in their capabilities: Unlike earlier models that focus on specific aspects of a multi-cellular organism, GenBio AI takes a holistic approach where multiscale foundation models are built in modules and integrated into a single system...
PR Newswire
19/12/2024
Interventional Cardiology Devices Market to Hit US$ 37.27 Billion by 2029 with…
Browse in-depth TOC on "Interventional Cardiology Devices Market" Browse in-depth TOC on "Interventional Cardiology Devices Market" 379 - Tables 62 - Figures 367 - Pages Based on Angioplasty stent type,the interventional cardiology devices market has been segmented into drug-eluting stents, bare-metal stents & bioabsorbable stents. Drug-eluting stents (DES) offer several advantages in cardiovascular procedures compared to bare metal stents (BMS). One of the primary...
PR Newswire
19/12/2024
Eurobio Scientific: EB Development obtains a significant majority of the capital…
Eurobio Scientific: EB Development obtains a significant majority of the capital with 88.9% held at the end of the Reopened Offer to continue its development with NextStage AM and IK PartnersParis, 19 December 2024 - 10.30amEurobio Scientific(FR0013240934, ALERS, PEA-PME eligible) andEB Developmentannounce the final outcome of the takeover bid initiated by EB Development (the " Offer "), based on the results published on 18 December by the Autorité des marchés financiers (AMF)...
Nasdaq GlobeNewswire
19/12/2024
Altri Comunicati
